Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
CN Stock MarketDetailed Quotes
Nanjing Vazyme Biotech (688105)
- 19.95
- +0.05+0.25%
Market Closed Apr 30 15:00 CST
7.93BMarket Cap-554.17P/E (TTM)
20.25High19.73Low1.99MlotVolume19.74Open19.90Prev Close39.74MTurnover0.50%Turnover RatioLossP/E (Static)397.73MShares26.7752wk High2.09P/B7.93BFloat Cap18.1752wk Low23.88Limit Up397.73MShs Float128.67Historical High15.92Limit Down2.61%Range %16.67Historical Low0.18Dividend TTM20.02Avg Price1.12MlotAsk0.90%Div Yield TTM1Lot Size795.49KlotBid
Nanjing Vazyme Biotech (688105) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 12.52%320.65M | -0.00%1.38B | -3.40%952.4M | -6.63%606.22M | -5.50%284.98M | 7.15%1.38B | 13.42%985.91M | 13.70%649.27M | -0.21%301.57M | -63.97%1.29B |
| Operating revenue | 12.52%320.65M | -0.00%1.38B | -3.40%952.4M | -6.63%606.22M | -5.50%284.98M | 7.15%1.38B | 13.42%985.91M | 13.70%649.27M | -0.21%301.57M | -63.97%1.29B |
| Total operating cost | 6.82%334.31M | -1.45%1.44B | -0.50%1.01B | -2.98%645.81M | -1.36%312.95M | 4.01%1.46B | 3.09%1.02B | -0.14%665.65M | -9.55%317.25M | -39.78%1.4B |
| Operating cost | 6.52%92.87M | 1.28%419.66M | -0.38%289.91M | -1.25%187.56M | -0.08%87.19M | 11.22%414.36M | 15.17%291.03M | 20.03%189.95M | -7.84%87.26M | -66.45%372.56M |
| Operating tax surcharges | 1,000.59%3.59M | -15.23%8.31M | -62.40%2.9M | -82.14%1.1M | -84.26%325.85K | 305.39%9.8M | 144.43%7.72M | 128.49%6.16M | 132.43%2.07M | -87.46%2.42M |
| Operating expense | 10.42%117.61M | 3.61%509.21M | 6.66%359.72M | 2.38%222.84M | 3.37%106.5M | 3.98%491.49M | 2.36%337.26M | -4.15%217.66M | -0.14%103.03M | -9.52%472.69M |
| Administration expense | -7.10%47.14M | -7.11%214.89M | -3.78%156.28M | -6.26%101.73M | -5.82%50.74M | -2.05%231.34M | -6.11%162.43M | -6.49%108.52M | -18.73%53.87M | -20.36%236.19M |
| Financial expense | 215.32%5.42M | -53.71%5.58M | -51.01%3.32M | 62.30%1.43M | 562.48%1.72M | 162.37%12.06M | 143.69%6.79M | 109.32%878.24K | -67.02%259.3K | -28.90%-19.33M |
| -Interest expense (Financial expense) | -11.93%6.16M | -11.33%24.17M | -16.76%19.56M | -11.80%13.74M | -22.00%6.99M | -22.27%27.25M | -14.63%23.5M | 2.12%15.58M | 77.83%8.96M | 181.08%35.07M |
| -Interest Income (Financial expense) | -458.46%-5.27M | 2.39%-17.75M | 27.56%-12.69M | 55.94%-7.19M | 90.07%-943.94K | 65.26%-18.19M | 54.80%-17.52M | 14.87%-16.31M | -47.11%-9.5M | -124.80%-52.36M |
| Research and development | 1.83%67.69M | -6.57%280.67M | -5.60%202.48M | -7.96%131.15M | -6.07%66.47M | -11.29%300.39M | -12.94%214.51M | -17.11%142.48M | -16.66%70.76M | -14.51%338.62M |
| Credit Impairment Loss | 95.79%-80.12K | 35.28%-17.33M | 75.76%-2.78M | 50.89%-4.02M | -16.20%-1.9M | -694.37%-26.77M | -155.13%-11.49M | -138.73%-8.19M | -113.33%-1.64M | 104.79%4.5M |
| Asset Impairment Loss | -215.97%-7.91M | -54.49%-38.33M | 17.05%-15.12M | 23.36%-9.04M | 71.23%-2.5M | 82.57%-24.81M | 77.89%-18.22M | 84.53%-11.79M | 85.65%-8.7M | 73.06%-142.32M |
| Other net revenue | ||||||||||
| Fair value change income | -24.01%13.96M | -5.01%52.59M | -0.21%42.72M | 10.57%30.67M | 10.67%18.37M | 28.63%55.36M | 29.25%42.81M | 6.44%27.74M | 18.27%16.6M | -6.23%43.04M |
| Invest income | -375.82%-2.98M | 13.31%5.14M | 14.14%3.47M | -18.45%1.38M | 104.09%1.08M | -42.40%4.54M | -55.45%3.04M | -30.68%1.69M | -74.39%529.19K | -81.29%7.88M |
| -Including: Investment income associates | ---4.1M | ---345.64 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | -10.33%279.89K | 85.99%-293.68K | 146.35%758.9K | 101.38%15.58K | -3.84%312.13K | -136.99%-2.1M | -129.77%-1.64M | -264.79%-1.13M | 678.81%324.61K | 2,726.13%5.67M |
| Other revenue | -76.44%1.71M | 36.76%19.05M | 91.56%15.56M | 94.03%9.73M | 163.10%7.27M | -85.82%13.93M | -79.03%8.12M | -65.67%5.01M | -80.34%2.76M | 663.71%98.2M |
| Operating profit | -62.32%-8.68M | 35.47%-39.62M | -57.31%-17.61M | -256.02%-10.85M | 7.91%-5.35M | 38.72%-61.39M | 88.50%-11.19M | 97.15%-3.05M | 91.31%-5.8M | -113.96%-100.18M |
| Add:Non operating Income | 1,118.53%4.66M | 51.93%1.7M | 192.64%1.61M | 315.87%1.37M | 308.48%382.71K | 3.98%1.12M | -44.23%550.68K | -69.43%328.87K | -66.48%93.69K | -21.35%1.08M |
| Less:Non operating expense | 98.41%-10.99K | 89.51%-212.25K | 122.91%555.24K | 106.49%161.57K | 79.33%-691.67K | -112.18%-2.02M | -120.29%-2.42M | -307.15%-2.49M | -332.01%-3.35M | -84.83%16.61M |
| Total profit | 6.29%-4M | 35.27%-37.71M | -101.39%-16.55M | -4,096.68%-9.65M | -80.61%-4.27M | 49.66%-58.25M | 92.41%-8.22M | 99.79%-229.91K | 96.52%-2.36M | -118.99%-115.71M |
| Less:Income tax cost | 2.24%-5.99M | 60.65%-15.2M | 19.69%-20.26M | 24.81%-11.68M | 15.37%-6.13M | 9.86%-38.63M | 17.36%-25.23M | 37.77%-15.53M | 56.85%-7.24M | -369.80%-42.85M |
| Net profit | 7.08%1.99M | -14.69%-22.51M | -78.19%3.71M | -86.72%2.03M | -61.92%1.86M | 73.07%-19.62M | 121.89%17.01M | 118.67%15.3M | 109.52%4.88M | -112.28%-72.86M |
| Net profit from continuing operation | 7.08%1.99M | -14.69%-22.51M | -78.19%3.71M | -86.72%2.03M | -61.92%1.86M | 73.07%-19.62M | 121.89%17.01M | 118.67%15.3M | 109.52%4.88M | -112.28%-72.86M |
| Less:Minority Profit | -4,011.11%-2.19M | -285.39%-5.89M | -153.68%-2.9M | -28.33%-1.1M | 84.36%-53.36K | 19.77%-1.53M | 13.71%-1.14M | 4.57%-854.49K | 41.72%-341.1K | -157.99%-1.91M |
| Net profit of parent company owners | 118.95%4.18M | 8.18%-16.61M | -63.57%6.62M | -80.63%3.13M | -63.39%1.91M | 74.50%-18.09M | 123.77%18.16M | 119.93%16.16M | 110.30%5.22M | -111.94%-70.96M |
| Earning per share | ||||||||||
| Basic earning per share | 100.00%0.01 | 20.00%-0.04 | -60.00%0.02 | -75.00%0.01 | -50.00%0.005 | 72.22%-0.05 | 126.32%0.05 | 120.00%0.04 | 107.69%0.01 | -112.08%-0.18 |
| Diluted earning per share | 100.00%0.01 | 20.00%-0.04 | -60.00%0.02 | -75.00%0.01 | -50.00%0.005 | 72.22%-0.05 | 126.32%0.05 | 120.00%0.04 | 107.69%0.01 | -112.08%-0.18 |
| Other composite income | -98.89%17.81K | 246.79%3.3M | 146.06%2.8M | 565.54%3.28M | 772.20%1.61M | -30.90%-2.25M | 136.49%1.14M | 79.08%-703.82K | -116.69%-239.32K | -1.72M |
| Other composite income of parent company owners | -95.21%77.04K | 248.55%3.34M | 147.33%2.81M | 565.54%3.28M | 772.20%1.61M | -30.87%-2.25M | 136.48%1.14M | 79.07%-703.87K | -116.69%-239.32K | ---1.72M |
| Other composite income of minority owners | ---59.23K | -8,812.03%-39.02K | -28,143.68%-14.31K | -445.00%-165.91 | ---- | -22,126.90%-437.87 | 445.83%51.01 | 266.06%48.09 | 14.74%-1.62 | ---1.97 |
| Total composite income | -42.12%2.01M | 12.21%-19.2M | -64.15%6.51M | -63.64%5.31M | -25.25%3.47M | 70.67%-21.87M | 122.45%18.15M | 117.11%14.6M | 109.31%4.64M | -112.57%-74.58M |
| Total composite income of parent company owners | 21.03%4.26M | 34.77%-13.27M | -51.14%9.43M | -58.55%6.41M | -29.30%3.52M | 72.01%-20.34M | 124.27%19.29M | 118.30%15.46M | 110.12%4.98M | -112.23%-72.68M |
| Total composite income of minority owners | -4,122.12%-2.25M | -287.83%-5.93M | -154.94%-2.92M | -28.36%-1.1M | 84.36%-53.36K | 19.75%-1.53M | 13.72%-1.14M | 4.58%-854.44K | 41.72%-341.11K | -157.99%-1.91M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | -- | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm